Healthy Living

4.66k followers • 10 symbols Watchlist by Yahoo Finance

This basket consists of stocks gaining popularity from health and wellness.

10 symbols

Zacks
Nike (NKE) Up 3.3% Since Last Earnings Report: Can It Continue?
Nike (NKE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Here's Why DexCom (DXCM) is a Great Momentum Stock to Buy
Does DexCom (DXCM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
2019 Holiday Retail Sales Rise 4.1%, Online a Key Driver
A sturdy labor market, rising income and improving confidence certainly encouraged consumers to spend more. While bargain hunters did hit the streets, enthusiasm for online shopping was palpable.
Zacks
Online Shoppers Help End 2019 Holiday Season on a Strong Note
The 2019 holiday season mirrors gains from increased investments and opportunities in the retail sector. The online channel continues to be the preferred shopping medium for customers.
Zacks
Tractor Supply Expands Feed Products With Triple Crown Launch
Tractor Supply (TSCO) is set to launch Triple Crown premium horse feed products. The move is likely to aid the top line and revive the stock's performance.
Zacks
Here's Why Steven Madden (SHOO) is a Solid Investment Option
Steven Madden's (SHOO) consistent expansion efforts and robust wholesale business position it well for growth.
Zacks
Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?
Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Financial Times
Let athletes enjoy their high-tech footwear
Of the hundreds of thousands of part-time athletes lining up for a park run this weekend, at least some will sport the latest Nike Vaporfly shoes. Fellow runners will regard them with a mixture of envy, disdain — “they look ridiculous” was one Financial Times athlete’s verdict on the fluorescent, chunky-heeled footwear — and, increasingly, suspicion. The top-of-the-range ZoomX Vaporfly Next%, which retails for £240, is living up to Nike’s billing as “the fastest shoe we’ve ever made”.
Zacks
Nevro (NVRO) Gains Ground on Solid Preliminary Q4 Results
Higher revenues and upbeat 2020 worldwide revenue outlook benefit Nevro's (NVRO) preliminary Q4 results.
Zacks
Crocs Hits New 52-Week High: Here's What Driving the Stock
Increased demand for clog shoes along with solid e-commerce and retail comps are likely to keep Croc's (CROX) stellar show on.
Zacks
DICK'S Sporting Gains on Merchandise Reshuffle, Exits Hunting
DICK'S Sporting (DKS) benefits from its decision to eliminate the hunting category from its stores and reallocating merchandise to improve athlete experience. This is bolstering its comps and margins.
Zacks
Allscripts Expands Partnership With PIH Health Through 2025
Encouraged by its solid EHR prospects, Allscripts (MDRX) expects a surge in its fourth-quarter 2019 bookings.
Zacks
Hanesbrands Down 15% in 6 Months: What's Hurting the Stock?
Hanesbrands (HBI) has long been struggling with sales decline at its Innerwear segment. Also, international presence has exposed it to currency headwinds.
Financial Times
Asics springs forward on reports of ban on Nike running shoes
Asics shares had a spring in their step on Thursday after reports that a key running shoe by rival Nike faced a ban for giving athletes an unfair advantage. Nike’s Vaporfly Next% long-distance shoes — described by the company as “the fastest shoe we’ve ever made” — face being blacklisted by World Athletics when it announces new rules on running shoes, according to a report by Runner’s World. Fuelled by rising debate over the role of technology advances in running shoes, athletics’ international governing body is set next month to consider new rules on the footwear that should be allowed in elite competition.
Zacks
Why this Cheap E-Commerce Stock Up 140% in a Year is a Strong Buy for 2020
Vipshop Holdings (VIPS) stock has soared 140% in the last year to crush Alibaba as the online discount retailer expands its customer base...
Zacks
Snap Up 5 Mega-Cap Stocks with Impressive Growth Prospects
Mega-caps, usually the largest and most established companies in the stock market, tend to be stable, and many of them pay dividends based on their earnings.
Zacks
Holiday Sales Are Not Impressing Investors
With earnings season in full swing, investors start to get some reports about the most recent holiday sales. We break it down to understand whats going on in the retail industry.
Zacks
Here's Why Hibbett (HIBB) Deserves a Place in Your Portfolio
Hibbett (HIBB) witnesses momentum on its growth endeavors, including store revitalization, e-commerce expansion and loyalty program. This is likely to drive growth in the year ahead.
Zacks
Dick's Sporting Goods, Canada Goose, JinkoSolar, Sunrun and Bloom Energy highlighted as Zacks Bull and Bear of the Day
Dick's Sporting Goods, Canada Goose, JinkoSolar, Sunrun and Bloom Energy highlighted as Zacks Bull and Bear of the Day
Zacks
Skechers' International & Direct-to-Consumer Units Bode Well
Skechers' (SKX) international and direct-to-consumer businesses are performing well. These are likely to continue driving the company's top line.
Zacks
V.F. Corp (VFC) to Post Q3 Earnings: What's in the Cards?
V.F. Corp's (VFC) third-quarter fiscal 2020 performance is likely to have been negatively impacted by softness in Timberland and Dickies brands.
Zacks
3 Large-Cap Dividend Stocks to Buy Now for Your 2020 Portfolio
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Reuters Videos
How your Fitbit can tell if you're getting sick
The Fitbit on your wrist can not only track your exercise habits, but it can also help tell if you're coming down with the flu - and warn health authorities to get ready to help you recover. A study in the U.S. found that heart rate and sleep data from the wearable fitness trackers, can predict and alert public health officials to real-time outbreaks of the flu more accurately than current surveillance methods. Data from more than 47,000 Fitbit users in five American states revealed that predictions of flu outbreaks in those areas were better - and faster. Traditional surveillance reports can take up to three weeks, meaning response measures, such as deploying vaccines or anti-virals, and advising patients on when to stay home, can take longer. Previous studies using crowd-sourced data, such as Google Flu Trends and Twitter have experienced variable levels of success. Experts say that's because it's impossible to separate people with flu from people who search online about it - due to the media and public attention present during outbreaks. The World Health Organization estimates that as many as 650,000 people die worldwide of respiratory conditions linked to seasonal flu every year.
Reuters Videos
Nike can gain from Vaporfly controversy: analysts
The running world is awaiting a decision by governing body World Athletics over what to do about Nike's Vaporfly shoe, a sneaker that has played a starring role in two of the biggest distance-running achievements last year. A sub two-hour marathon by Eliud Kipchoge and a record-breaking run by Brigid Kosgei. Their stunning performances have sparked heated debate over whether their shoes gave them an unfair advantage. And now, a group at World Athletics is examining what to do about the high-tech sneakers. Among the options facing the organization is to impose a wholesale ban on the shoes or take more limited measures to deal with their carbon plate and foam sole technology. Independent studies have concluded that the shoes improve metabolic efficiency by 4%, though that does not necessarily mean a runner will be 4% faster. All Nike says on its website that the shoe, which will run you $250, has a "built-in secret weapon." But despite all the controversy, analysts tell Reuters the publicity could actually boost sales, especially among amateur runners looking for more spring in their step, since they wouldn't be affected by any ban.